Trial Review

Please note the ANZCTR website will be unavailable from 1-2 pm (AEST) on Thursday, the 19th of June for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05327114




Registration number
NCT05327114
Ethics application status
Date submitted
7/04/2022
Date registered
14/04/2022
Date last updated
11/06/2025

Titles & IDs
Public title
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Scientific title
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Secondary ID [1] 0 0
80202135CDP3001
Secondary ID [2] 0 0
CR109195
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 0 0
Condition category
Condition code
Neurological 0 0 0 0
Other neurological disorders
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Neurological 0 0 0 0
Neurodegenerative diseases

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Nipocalimab
Treatment: Drugs - Placebo

Experimental: Nipocalimab - Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo comparator: Placebo - Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.


Treatment: Drugs: Nipocalimab
Nipocalimab will be administered intravenously.

Treatment: Drugs: Placebo
Placebo will be administered intravenously.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Stage B: Time to First Occurrence of a Relapse Event
Assessment method [1] 0 0
Stage B time to first occurrence of a relapse event will be reported.
Timepoint [1] 0 0
Up to 52 weeks
Secondary outcome [1] 0 0
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Assessment method [1] 0 0
Time to initial confirmed ECI will be reported.
Timepoint [1] 0 0
12 weeks
Secondary outcome [2] 0 0
Stage A: Percentage of Responders as Determined by ECI
Assessment method [2] 0 0
Stage A percentage of responders as determined by ECI will be reported.
Timepoint [2] 0 0
12 weeks
Secondary outcome [3] 0 0
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Assessment method [3] 0 0
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.
Timepoint [3] 0 0
Baseline to 12 weeks
Secondary outcome [4] 0 0
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Assessment method [4] 0 0
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 \[no visible contraction\] to 5 \[normal\]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.
Timepoint [4] 0 0
Baseline to 12 weeks
Secondary outcome [5] 0 0
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Assessment method [5] 0 0
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.
Timepoint [5] 0 0
Baseline to 12 weeks
Secondary outcome [6] 0 0
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Assessment method [6] 0 0
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).
Timepoint [6] 0 0
Baseline to 12 weeks
Secondary outcome [7] 0 0
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Assessment method [7] 0 0
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).
Timepoint [7] 0 0
Baseline to 12 weeks
Secondary outcome [8] 0 0
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Assessment method [8] 0 0
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.
Timepoint [8] 0 0
Up to 52 weeks
Secondary outcome [9] 0 0
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Assessment method [9] 0 0
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.
Timepoint [9] 0 0
Up to 52 weeks
Secondary outcome [10] 0 0
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Assessment method [10] 0 0
Change from Stage B baseline over time in adjusted INCAT disability score will be reported.
Timepoint [10] 0 0
Up to 52 weeks
Secondary outcome [11] 0 0
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Assessment method [11] 0 0
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.
Timepoint [11] 0 0
Up to 52 weeks
Secondary outcome [12] 0 0
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Assessment method [12] 0 0
Change from Stage B baseline over time in I-RODS centile score will be reported.
Timepoint [12] 0 0
Up to 52 weeks
Secondary outcome [13] 0 0
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Assessment method [13] 0 0
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).
Timepoint [13] 0 0
Up to 52 weeks
Secondary outcome [14] 0 0
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Assessment method [14] 0 0
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).
Timepoint [14] 0 0
Up to 52 weeks
Secondary outcome [15] 0 0
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Assessment method [15] 0 0
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.
Timepoint [15] 0 0
Up to 52 weeks
Secondary outcome [16] 0 0
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Assessment method [16] 0 0
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment
Timepoint [16] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [17] 0 0
Percentage of Participants with Serious Adverse Events (SAEs)
Assessment method [17] 0 0
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.
Timepoint [17] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [18] 0 0
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Assessment method [18] 0 0
Number of participants with change in ECG values over time will be reported.
Timepoint [18] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [19] 0 0
Number of Participants with Change in Vital Signs Values Over Time
Assessment method [19] 0 0
Number of participants with change in vital signs values over time will be reported.
Timepoint [19] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [20] 0 0
Number of Participants with Change in Clinical Laboratory Values Over Time
Assessment method [20] 0 0
Number of participants with change in clinical laboratory values over time will be reported.
Timepoint [20] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [21] 0 0
Number of Participants with Clinically Significant ECG Abnormalities
Assessment method [21] 0 0
Number of participants with clinically significant ECG abnormalities will be reported.
Timepoint [21] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [22] 0 0
Number of Participants with Clinically Significant Vital Signs Abnormalities
Assessment method [22] 0 0
Number of participants with clinically significant vital signs abnormalities will be reported.
Timepoint [22] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [23] 0 0
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Assessment method [23] 0 0
Number of participants with clinically significant clinical laboratory abnormalities will be reported.
Timepoint [23] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [24] 0 0
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Assessment method [24] 0 0
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.
Timepoint [24] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [25] 0 0
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Assessment method [25] 0 0
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.
Timepoint [25] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [26] 0 0
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Assessment method [26] 0 0
Number of participants with ADA to Nipocalimab will be reported.
Timepoint [26] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [27] 0 0
Titers of ADA to Nipocalimab
Assessment method [27] 0 0
Titers of ADA to nipocalimab will be reported.
Timepoint [27] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [28] 0 0
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Assessment method [28] 0 0
Number of participants with NAb to Nipocalimab will be reported.
Timepoint [28] 0 0
Stage A: 12 weeks; Stage B: Up to 52 weeks
Secondary outcome [29] 0 0
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Assessment method [29] 0 0
Change from baseline in total serum IgG concentrations levels over time will be reported.
Timepoint [29] 0 0
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Eligibility
Key inclusion criteria
* Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
* Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
* Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
* Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
* Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
* Other protocol-defined inclusion criteria will apply
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
* Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
* Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
* Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
* Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
* Other protocol-defined exclusion criteria will apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2028
Actual
Sample size
Target
201
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [2] 0 0
Gold Coast University Hospital - Parkwood
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment postcode(s) [2] 0 0
4215 - Parkwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Maryland
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Wisconsin
Country [12] 0 0
China
State/province [12] 0 0
Beijing
Country [13] 0 0
China
State/province [13] 0 0
Changchun
Country [14] 0 0
China
State/province [14] 0 0
Changsha
Country [15] 0 0
China
State/province [15] 0 0
Chifeng
Country [16] 0 0
China
State/province [16] 0 0
Fuzhou
Country [17] 0 0
China
State/province [17] 0 0
Guang Zhou
Country [18] 0 0
China
State/province [18] 0 0
Jinan
Country [19] 0 0
China
State/province [19] 0 0
Nanchang
Country [20] 0 0
China
State/province [20] 0 0
Shanghai
Country [21] 0 0
China
State/province [21] 0 0
Xi'an
Country [22] 0 0
Colombia
State/province [22] 0 0
Floridablanca
Country [23] 0 0
Colombia
State/province [23] 0 0
Medellin
Country [24] 0 0
Czechia
State/province [24] 0 0
Hradec Králové
Country [25] 0 0
Czechia
State/province [25] 0 0
Ostrava
Country [26] 0 0
Czechia
State/province [26] 0 0
Pardubice
Country [27] 0 0
France
State/province [27] 0 0
Bordeaux
Country [28] 0 0
France
State/province [28] 0 0
Bron
Country [29] 0 0
France
State/province [29] 0 0
Le Kremlin Bicêtre
Country [30] 0 0
France
State/province [30] 0 0
Nice
Country [31] 0 0
France
State/province [31] 0 0
Strasbourg
Country [32] 0 0
Germany
State/province [32] 0 0
Bochum
Country [33] 0 0
Germany
State/province [33] 0 0
Hannover
Country [34] 0 0
Germany
State/province [34] 0 0
Leipzig
Country [35] 0 0
Germany
State/province [35] 0 0
Potsdam
Country [36] 0 0
Greece
State/province [36] 0 0
Athens
Country [37] 0 0
Greece
State/province [37] 0 0
Patras
Country [38] 0 0
Greece
State/province [38] 0 0
Thessaloniki
Country [39] 0 0
Japan
State/province [39] 0 0
Asahikawa
Country [40] 0 0
Japan
State/province [40] 0 0
Bunkyo ku
Country [41] 0 0
Japan
State/province [41] 0 0
Chiba-shi
Country [42] 0 0
Japan
State/province [42] 0 0
Hamamatsu
Country [43] 0 0
Japan
State/province [43] 0 0
Isehara
Country [44] 0 0
Japan
State/province [44] 0 0
Kobe City
Country [45] 0 0
Japan
State/province [45] 0 0
Kodaira-shi
Country [46] 0 0
Japan
State/province [46] 0 0
Koshigaya
Country [47] 0 0
Japan
State/province [47] 0 0
Kumamoto
Country [48] 0 0
Japan
State/province [48] 0 0
Nagoya-shi
Country [49] 0 0
Japan
State/province [49] 0 0
Nagoya
Country [50] 0 0
Japan
State/province [50] 0 0
Osaka Sayama shi
Country [51] 0 0
Japan
State/province [51] 0 0
Sendai-City
Country [52] 0 0
Japan
State/province [52] 0 0
Shimotsuga Gun
Country [53] 0 0
Japan
State/province [53] 0 0
Shinjuku-ku
Country [54] 0 0
Japan
State/province [54] 0 0
Tenri
Country [55] 0 0
Japan
State/province [55] 0 0
Toon-shi
Country [56] 0 0
Japan
State/province [56] 0 0
Toyama-shi
Country [57] 0 0
Japan
State/province [57] 0 0
Ube
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seoul
Country [59] 0 0
Mexico
State/province [59] 0 0
Monterrey
Country [60] 0 0
Mexico
State/province [60] 0 0
Tlalnepantla
Country [61] 0 0
Poland
State/province [61] 0 0
Chorzow
Country [62] 0 0
Poland
State/province [62] 0 0
Krakow
Country [63] 0 0
Poland
State/province [63] 0 0
Lublin
Country [64] 0 0
Poland
State/province [64] 0 0
Poznan
Country [65] 0 0
Portugal
State/province [65] 0 0
Almada
Country [66] 0 0
Portugal
State/province [66] 0 0
Braga
Country [67] 0 0
Portugal
State/province [67] 0 0
Porto
Country [68] 0 0
Spain
State/province [68] 0 0
Alicante
Country [69] 0 0
Spain
State/province [69] 0 0
Barcelona
Country [70] 0 0
Spain
State/province [70] 0 0
Bilbao
Country [71] 0 0
Spain
State/province [71] 0 0
Madrid
Country [72] 0 0
Spain
State/province [72] 0 0
Sevilla
Country [73] 0 0
Taiwan
State/province [73] 0 0
Kaohsiung
Country [74] 0 0
Taiwan
State/province [74] 0 0
Taipei
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Birmingham
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Glasgow
Country [77] 0 0
United Kingdom
State/province [77] 0 0
London
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Contact
Address 0 0
Country 0 0
Phone 0 0
844-434-4210
Email 0 0
Participate-In-This-Study1@its.jnj.com
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05327114